InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (11 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
11
T+90 hit rate
80%
T+90 mean return
+9.3%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Gano Kyle, Chief Executive Officer. Officer active across 1 company, notably Neurocrine Biosciences INC. Aggregated, 20 disclosures have been recorded. Split: 0 buy · 11 sells. Total volume traded: €1.2m. Activity tracked since 5 January 2022. The latest transaction was filed on 16 January 2026 (Levée d'options). Regulator: SEC (Form 4). All data is openly available.
Declarations20 total
34,588 shares@ US$35.9940.0% of flowCommon StockSEC:0001567160-26-000002
34,588 shares@ US$35.990.0076% mcap40.0% of flowCommon StockSEC:0001567160-26-000002:0
2,566 shares0Common StockSEC:0000914475-25-000063:0
1,860 shares0Common StockSEC:0000914475-25-000049:0
2,927 shares0Common StockSEC:0000914475-25-000025:0
4,812 shares@ US$32.993.0% of flowCommon StockSEC:0000914475-25-000004:0
1,352 shares@ US$132.89473.2% of flowCommon StockSEC:0000914475-24-000072:0
1,600 shares@ US$142.20134.1% of flowCommon StockSEC:0000914475-24-000045:0
1,541 shares@ US$140.6963.9% of flowCommon StockSEC:0000914475-24-000027:0
68,884 shares@ US$19.5923.7% of flowCommon StockSEC:0000914475-24-000007:0
2,132 shares@ US$107.40754.1% of flowCommon StockSEC:0001209191-23-047135:0
1,600 shares@ US$105.64223.0% of flowCommon StockSEC:0001209191-23-007910:0
1,541 shares@ US$109.98473.0% of flowCommon StockSEC:0001209191-23-006275:0
703 shares@ US$80.6830.0003% mcap1.8% of flowCommon StockSEC:0001209191-22-008207:0
703 shares@ US$80.6830.0003% mcap3.7% of flowCommon StockSEC:0001209191-22-008207
28,266 shares@ US$8.660.0015% mcap8.1% of flowCommon StockSEC:0001209191-22-002529:0
28,266 shares@ US$8.660.0015% mcap16.2% of flowCommon StockSEC:0001209191-22-002529
1,375 sharesCommon StockSEC:0001209191-16-095849:0
1,625 sharesCommon StockSEC:0001209191-16-092886:0
1,250 sharesCommon StockSEC:0001209191-16-091252:0
20 of 20 declarations
About Gano Kyle
Kyle Gano serves as Chief Executive Officer and Chief Business Development Officer at Neurocrine Biosciences Inc. He leads the company's strategic initiatives and oversees the development of new business opportunities. Kyle brings expertise in management and product development, contributing to innovation and growth at Neurocrine.
